文献速递垂体与肾上腺疾病

垂体腺瘤的免疫特征及用于预测免疫治疗反应性的新型免疫分类

The Immune Profile of Pituitary Adenomas and a Novel Immune Classification for Predicting Immunotherapy Responsiveness.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

该研究纳入259例垂体腺瘤和20例正常垂体的转录组数据,用ImmuCellAI算法估算24种肿瘤浸润免疫细胞丰度和免疫检查点分子表达。结果显示T细胞在所有亚型中占主导,肿瘤大小、患者年龄及USP8突变与免疫细胞分布相关,并识别出3个免疫聚类,其中聚类1和2为「热」免疫微环境,预测对免疫治疗反应性高于聚类3。

要点

  • 垂体腺瘤与正常垂体的肿瘤浸润免疫细胞分布不同,且在不同亚型间存在差异。
  • T细胞在所有垂体腺瘤亚型的免疫微环境中占主导地位。
  • 基于免疫细胞分布识别出3个免疫聚类,聚类1和2为「热」微环境,预测免疫治疗反应性高于聚类3。

核心结论

  • 研究总结了垂体腺瘤的免疫特征并识别出3个新型免疫聚类,为进一步免疫研究和免疫治疗策略提供基础。

研究设计与样本

  • 纳入259例垂体腺瘤和20例正常垂体的转录组数据进行分析。
  • 使用ImmuCellAI算法估算24种肿瘤浸润免疫细胞(TIIC)的丰度和免疫检查点分子(ICM)的表达。

主要发现

  • 垂体腺瘤与正常垂体的TIIC分布不同,且在不同垂体腺瘤亚型间存在差异。
  • T细胞在所有垂体腺瘤亚型的免疫微环境中占主导。
  • 肿瘤大小和患者年龄与TIIC丰度相关,促肾上腺皮质激素细胞腺瘤中的USP8突变影响瘤内TIIC分布。
  • 基于TIIC分布识别出3个免疫聚类,各聚类ICM表达特征不同并与肿瘤发生发展相关通路相关。
  • 聚类1中CTLA4/CD86表达上调,聚类2中PD1/PD-L2表达上调;聚类1和2为「热」免疫微环境,预测免疫治疗反应性高于整体呈「冷」免疫微环境的聚类3。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The tumor immune microenvironment is associated with clinical outcomes and immunotherapy responsiveness. OBJECTIVE: To investigate the intratumoral immune profile of pituitary adenomas (PAs) and its clinical relevance and to explore a novel immune classification for predicting immunotherapy responsiveness. DESIGN, PATIENTS, AND METHODS: The transcriptomic data from 259 PAs and 20 normal pituitaries were included for analysis. The ImmuCellAI algorithm was used to estimate the abundance of 24 types of tumor-infiltrating immune cells (TIICs) and the expression of immune checkpoint molecules (ICMs). RESULTS: The distributions of TIICs differed between PAs and normal pituitaries and varied among PA subtypes. T cells dominated the immune microenvironment across all subtypes of PAs. The tumor size and patient age were correlated with the TIIC abundance, and the ubiquitin-specific protease 8 (USP8) mutation in corticotroph adenomas influenced the intratumoral TIIC distributions. Three immune clusters were identified across PAs based on the TIIC distributions. Each cluster of PAs showed unique features of ICM expression that were correlated with distinct pathways related to tumor development and progression. CTLA4/CD86 expression was upregulated in cluster 1, whereas programmed cell death protein 1/programmed cell death 1 ligand 2 (PD1/PD-L2) expression was upregulated in cluster 2. Clusters 1 and 2 exhibited a "hot" immune microenvironment and were predicted to exhibit higher immunotherapy responsiveness than cluster 3, which exhibited an overall "cold" immune microenvironment. CONCLUSIONS: We summarized the immune profile of PAs and identified 3 novel immune clusters. These findings establish a foundation for further immune studies on PAs and provide new insights into immunotherapy strategies for PAs.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Wang Z, Guo X, Gao L, et al. The Immune Profile of Pituitary Adenomas and a Novel Immune Classification for Predicting Immunotherapy Responsiveness. J Clin Endocrinol Metab. 2020. PMID: 32652004. doi:10.1210/clinem/dgaa449

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。